← All organizations
Highest phase reached
Phase 2
First clinical trial
Mar 12, 2020Last known activity
Apr 14, 2022
Timeline
2010s
- May 1, 2016
Celularity, Inc.— Founded
Drugs by trial phase (8 distinct, 6 trials)
Phase 2 (8 own, 0 via acquisition)
Indications
Studied for
- Astrocytoma
- Blood Coagulation Disorders
- Blood Protein Disorders
- Cardiovascular Diseases
- Communicable Diseases
- Coronaviridae Infections
- Coronavirus Infections
- Disease
- Glioblastoma
- Hematologic Diseases
- Hematologic Neoplasms
- Hemorrhagic Disorders
- Hemostatic Disorders
- Immune System Diseases
- Immunoproliferative Disorders
- Infections
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Diseases
- Lymphoproliferative Disorders
- Multiple Myeloma
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms, Plasma Cell
- Nidovirales Infections
- Paraproteinemias
- Pneumonia
- Pneumonia, Viral
- Respiratory Tract Diseases
- Respiratory Tract Infections
- RNA Virus Infections
- Severe Acute Respiratory Syndrome
- Vascular Diseases
- Virus Diseases
Recent trials (10)
- NCT05207722Lead sponsorPhase 1/Phase 2Apr 14, 2022
- NCT05207722Study directorPhase 1/Phase 2Apr 14, 2022
- NCT05218408Lead sponsorPhase 1/Phase 2Mar 8, 2022
- NCT05218408Study directorPhase 1/Phase 2Mar 8, 2022
- NCT04489420Study directorPhase 1Oct 1, 2020
- NCT04489420Lead sponsorPhase 1Oct 1, 2020
- NCT04365101Lead sponsorPhase 1/Phase 2May 13, 2020
- NCT04310592Lead sponsorPhase 1Mar 12, 2020
- NCT04309084Lead sponsorPhase 1/Phase 2Mar 12, 2020
- NCT04310592Study directorPhase 1Mar 12, 2020
Details
- Founded
- Florham Park, NJ, US May 1, 2016
- Last known activity
- Apr 14, 2022